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Abstract
Background The SPYRAL HTN clinical trial program was initiated with two 80-patient pilot studies, SPYRAL HTN-
OFF MED and SPYRAL HTN-ON MED, which provided biological proof of principle that renal denervation has a blood 
pressure-lowering effect versus sham controls for subjects with uncontrolled hypertension in the absence or presence of 
antihypertensive medications, respectively.
Trial design Two multicenter, prospective, randomized, sham-controlled trials have been designed to evaluate the safety and 
efficacy of catheter-based renal denervation for the reduction of blood pressure in subjects with hypertension in the absence 
(SPYRAL HTN-OFF MED Pivotal) or presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications. 
The primary efficacy endpoint is baseline-adjusted change from baseline in 24-h ambulatory systolic blood pressure. The 
primary safety endpoint is incidence of major adverse events at 1 month after randomization (or 6 months in cases of new 
renal artery stenosis). Both trials utilize a Bayesian design to allow for prespecified interim analyses to take place, and thus, 
the final sample sizes are dependent on whether enrollment is stopped at the first or second interim analysis. SPYRAL HTN-
OFF MED Pivotal will enroll up to 300 subjects and SPYRAL HTN-ON MED Expansion will enroll up to 221 subjects. A 
novel Bayesian power prior approach will leverage historical information from the pilot studies, with a degree of discounting 
determined by the level of agreement with data from the prospectively powered studies.
Conclusions The Bayesian paradigm represents a novel and promising approach in device-based hypertension trials.
Clinical trial registration URL: https ://www.clini caltr ials.gov. Unique identifier: NCT02439749 (SPYRAL HTN-OFF MED 
Pivotal) and NCT02439775 (SPYRAL HTN-ON MED Expansion).
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Abbreviations
ABPM  Ambulatory blood pressure monitor
CEC  Clinical Events Committee
DBP  Diastolic blood pressure
DSMB  Data Safety Monitoring Board
eGFR  Estimated glomerular filtration rate
SBP  Systolic blood pressure
Introduction
Catheter-based renal denervation has been shown to decrease 
central sympathetic activity, with early clinical trials show-
ing blood pressure-lowering effects in subjects with uncon-
trolled hypertension [1, 2]. Despite these early findings, the 
randomized, blinded, sham-controlled SYMPLICTY HTN-3 
trial showed a statistically significant reduction from base-
line in blood pressure in both the renal denervation and sham 
control groups, but the difference between the two groups 
was not significant [3]. A post hoc analysis showed that lack 
of adherence to antihypertensive medication regimens, and 
fewer ablations during the denervation procedure were asso-
ciated with decreased systolic blood pressure (SBP) effects 
in this trial [4].
The SPYRAL HTN clinical trial program was initiated 
with pilot studies that were designed to control for the poten-
tially confounding effects of the variables identified in the 
post hoc analysis. Separate pilot studies, SPYRAL HTN-
OFF MED and SPYRAL HTN-ON MED, reaffirmed the 
biological proof of principle that renal denervation had a sig-
nificant blood pressure-lowering effect versus sham controls 
for subjects with uncontrolled hypertension in the absence 
or presence of antihypertensive medications, respectively 
[5, 6]. An important difference from previous studies was 
use of a redesigned catheter and treatment algorithms that 
allow for more distal circumferential treatment of the main 
and branch vessels.
To transition seamlessly into the next stage of the pro-
gram, the prospectively powered SPYRAL HTN-OFF MED 
Pivotal trial and SPYRAL HTN-ON MED Expansion trial 
will leverage information from the pilot studies, which 
share a similar design. This is achieved with the use of a 
novel Bayesian design that leverages information from these 
pilot studies, and applies a discount function that adjusts 
the influence of the historical information based on level 
of agreement with the data from the prospectively powered 
studies [7–9]. Additionally, the design incorporates prespeci-
fied interim analyses. Such approaches, particularly in the 
Bayesian paradigm, have become adopted in recent clinical 
trials and have shown great promise [10, 11]. This approach 
allows for the same rigor as the Frequentist approach but 
with more efficient use of data, faster timelines, and reduced 
cost [12]. In this report, we describe the use of a unique 
version of this design in the SPYRAL HTN-OFF MED Piv-
otal and SPYRAL HTN-ON MED Expansion trials.
Methods
Program overview
Two multicenter, international, prospective, single blinded, 
randomized, sham-controlled trials in the SPYRAL HTN 
clinical trial program are evaluating the safety and efficacy 
of catheter-based renal denervation for the reduction of 
blood pressure in subjects with uncontrolled hypertension. 
The SPYRAL HTN-OFF MED Pivotal trial is evaluating 
catheter-based renal denervation for the reduction of blood 
pressure in the absence of antihypertensive medications, 
and the SPYRAL HTN-ON MED Expansion trial in the 
presence of 1–3 guideline-recommended antihypertensive 
medications. In each trial, subjects randomized to the renal 
denervation group undergo the renal denervation procedure, 
and those randomized to the control group receive a sham 
procedure, with the subject remaining on the catheterization 
table for at least 20 min before sheath removal.
The SPYRAL HTN-OFF MED Pivotal and SPYRAL 
HTN-ON MED Expansion trials are sponsored by Medtronic 
(Santa Rosa, CA, USA), and were designed by the princi-
pal investigators, steering committees, and sponsor in col-
laboration with the FDA and followed recommendations 
provided by European and US consensus documents [13, 
14]. The trials are being conducted in accordance with the 
Declaration of Helsinki 2013, the international standard ISO 
14155:2011, and local laws and regulations, including data 
protection laws. The study protocols were approved by the 
institutional review boards and/or ethics committees at each 
clinical site, and written informed consent is provided by all 
subjects before enrollment. The trials are registered at Clini-
calTrials.gov with the identifiers NCT02439749 (SPYRAL 
HTN-OFF MED Pivotal) and NCT02439775 (SPYRAL 
HTN-ON MED Expansion).
Trial design
The SPYRAL HTN-OFF MED Pivotal and SPYRAL HTN-
ON MED Expansion trials will each include 80 subjects 
from the respective pilot studies for use as an informative 
prior (see section on “Statistics”, “Determination of sample 
size and prespecified interim looks”). For SPYRAL HTN-
OFF MED Pivotal, additional 247–353 subjects will be ran-
domized for an overall sample size up to 433 subjects. For 
SPYRAL HTN-ON MED Expansion, additional 175–260 
subjects will be randomized for an overall sample size up 
to 340 subjects. For both trials, subjects are being enrolled 
in study sites across the United States, Canada, Japan, 
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Australia, and countries where the CE mark applies (up to 
50 sites for SPYRAL HTN-OFF MED Pivotal and up to 55 
sites for SPYRAL HTN-ON MED Expansion).
Eligible subjects are 20–80 years old and have hyperten-
sion, defined as office systolic blood pressure (SBP) ≥ 150 mm 
Hg and < 180  mm Hg, office diastolic blood pressure 
(DBP) ≥ 90  mm Hg, and mean 24  h SBP ≥ 140  mm Hg 
and < 170 mm Hg. For the SPYRAL HTN-OFF MED Pivotal 
trial, subjects must be naïve to antihypertensive medications or 
willing to discontinue all antihypertensive medications from the 
first screening visit through assessment of the primary efficacy 
endpoint (3 months post-procedure). For the SPYRAL HTN-
ON MED Expansion trial, subjects must be taking 1–3 antihy-
pertensive medications prescribed at ≥ 50% of the maximum 
manufacturer’s dosage. Antihypertensive medication classes 
must include a thiazide-type diuretic, a dihydropyridine cal-
cium channel blocker, an angiotensin-converting enzyme-I/
angiotensin-II receptor blocker, and/or a beta-blocker. Subjects 
must be on a stable dose of each medication for at least 6 weeks 
before the first screening visit and continuing until a confirma-
tory second screening visit. When prescribed other qualifying 
medications, 12.5 mg hydrochlorothiazide is acceptable as the 
minimum dosage. A complete list of inclusion and exclusion 
criteria are presented in Table 1.
The details of each trial design are shown in Fig. 1. Sub-
jects undergo a series of screening visits before randomiza-
tion into treatment groups. At the first visit (Screening Visit 1), 
subjects are screened based on medical history and office SBP. 
After a continued medication stabilization period of 2–4 weeks 
(SPYRAL HTN-ON MED Expansion) or medication-washout 
period of up to 4 weeks (SPYRAL HTN-OFF MED Pivotal), 
eligible subjects proceed to a second visit (Screening Visit 2) 
where they are screened for potential randomization based on 
office BP and clinical assessment. Subjects who continue to 
meet eligibility criteria at this visit are fitted with a 24 h ABPM 
device as a final screen before randomization. Baseline BP 
measurements are obtained at Screening Visit 2.
Subjects who meet the 24 h ambulatory SBP criteria pro-
ceed to renal angiography to confirm that renal anatomy 
meets eligibility criteria. Upon confirmation of final eligibil-
ity criteria, subjects are randomized into treatment groups 
(1:1 denervation to control for SPYRAL HTN-OFF MED 
Pivotal, 2:1 denervation to control for SPYRAL HTN-ON 
MED Expansion). Subjects are blinded during renal angiog-
raphy as to what treatment procedure (RDN or sham) they 
received and, following the angiogram, those randomized 
to the renal denervation group proceed directly to the renal 
artery denervation procedure. To ensure potential contribu-
tory factors other than the renal denervation procedure are 
controlled for, a sham control, as included in the SYMPLIC-
ITY HTN-3 trial, is included in both trials. As such, those 
in the control group receive a sham procedure, where the 
subject remains on the catheterization lab table for at least 
20 min prior to sheath removal. All subjects receive con-
scious sedation to ensure proper blinding.
For SPYRAL HTN-OFF MED Pivotal, subjects return for 
office follow-up visits at 2, 4, and 8 (± 3 days) weeks, 3 and 
6 (± 14 days) months, and 12, 24, and 36 (± 30 days) months 
post-procedure. Phone follow-ups are also conducted at 6 
and 10 (± 3 days) weeks. Upon completion of the 3-month 
visit, subjects with office SBP ≥ 140 mm Hg will receive 
antihypertensive medications according to a medication 
re-introduction protocol (supplement). For SPYRAL HTN-
ON MED Expansion, subjects return for office follow-up 
visits at 1, 3, and 6 (± 14 days) months and 12, 24, and 
36 (± 30 days) months post-procedure. Antihypertensive 
medication changes are not allowed through 6 months in 
the SPRYAL HTN-ON MED Expansion trial.
Each trial also has an escape protocol for subjects who 
need to adjust antihypertensive medications after randomiza-
tion. Subjects who met antihypertensive medication escape 
criteria will have blood pressure measurements analyzed 
with Last Observation Carried Forward (LOCF, see section 
on “Statistics”, “Analysis populations”). For both trials, if 
a subject has office SBP ≥ 180 mm Hg or there is a safety 
concern between randomization and 3 months (SPYRAL 
HTN-OFF MED Pivotal) or 6 months (SPYRAL HTN-ON 
MED Expansion) post-procedure, the subject will be seen a 
second time within 72 h for a repeat office SBP. If the sub-
ject’s office SBP remains ≥ 180 mm Hg, antihypertensive 
medications will be reinstated per the investigator’s discre-
tion. For SPYRAL HTN-ON MED Expansion, if a subject 
has office SBP < 115 mm Hg associated with symptoms of 
hypotension, the antihypertensive medication regimen may 
be changed and/or other therapy administered per the inves-
tigator’s discretion.
In both trials, subjects in the control group may crossover 
to receive renal denervation after completing the 6-month 
follow-up visit. Required baseline data must be collected and 
the subject must not meet any anatomic or estimated glomer-
ular filtration rate (eGFR) exclusion criteria to receive the 
crossover renal denervation procedure. After the procedure, 
crossover subjects will undergo follow-up visits at 1, 3, and 6 
(± 14 days) months and 12 and 24 (± 30 days) months (also 
36 months for SPYRAL HTN-OFF MED Pivotal). Subjects 
who do not meet eligibility criteria for the crossover proce-
dure will continue follow-up visits according to the original 
schedule.
Screening, randomization, and blinding
Screening details have been previously described for each 
trial [5, 6, 15]. Randomization is stratified by study center, 
and each site can access randomization allocation via a pass-
word-protected system that can only be accessed by those 
approved by the sponsor.
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Table 1  Inclusion and exclusion criteria for the SPYRAL HTN-OFF MED Pivotal and SPYRAL HTN-ON MED Expansion trials
Inclusion criteria
Age 20–80 years at enrolment
Office SBP < 180 mm  Hga,b
Office SBP ≥ 150 mm  Hga,c
Office DBP ≥ 90 mm  Hga,c
24 h ABPM average SBP ≥ 140 mm Hg and < 170 mm  Hgd−f
SPYRAL HTN-OFF MED Pivotal only: willing to discontinue current antihypertensive medications at Screening Visit 1 through the 3-month 
post-procedure visit
Agrees to have all study procedures performed, is competent and willing to provide written informed consent
Exclusion criteria
Undergone prior renal denervation
Renal anatomy that is ineligible for treatment
 Main renal artery for each kidney is < 3 mm or > 8 mm
 Lack of main renal arterial vessel that does not allow four simultaneous quadratic ablations in main renal artery or equivalent
Presence of fibromuscular dysplasia
> 50% stenosis in any treatable vessel
Renal artery stent placed < 3 months prior to denervation procedure
Presence of aneurysm defined as any localized increase in vessel diameter
Treatment area within 5 mm segment in the renal artery contains an atheroma, calcification, or renal artery stent
eGFR < 45 mL/min/1.73  m2, using the 4-variable MDRD  calculationg
Taking SGLT2 inhibitors or GLP-1 agonists that have been prescribed < 90 days prior to Screening Visit 1 or without plan to remain on those 
medications for duration of trial
≥ 1 episode of orthostatic hypotension not related to medication changes within the past year or a reduction in SBP ≥ 20 mm Hg or 
DBP ≥ 10 mm Hg within 3 min of standing coupled with symptoms during the screening process
Requires chronic oxygen support or mechanical ventilation (other than nocturnal respiratory support for sleep apnea)
Documented primary pulmonary hypertension
Untreated secondary cause of hypertension (known or suspected) or taking medications that increase sympathetic tone that could contribute to 
hypertension
Frequent intermittent or chronic pain that results in treatment with NSAIDs for ≥ 2 days per week over the month prior to enrollment (aspirin and 
clopidogrel permitted for cardiovascular risk reduction)
HIV on anti-retroviral drug therapy but without documentation that hypertension preceded initiation of anti-retroviral drug therapy
SPYRAL HTN-OFF MED Pivotal: history of myocardial infarction, stable or unstable angina, transient ischemic attack, cerebrovascular acci-
dent, heart failure, or atrial fibrillation within 3 months of enrolment
SPYRAL HTN-ON MED Expansion: History of myocardial infarction, unstable angina pectoris, syncope, transient ischemic attack, or a 
cerebrovascular accident within 3 months of the screening period, or widespread atherosclerosis with documented intravascular thrombosis or 
unstable plaques
Peptic ulcer or gastrointestinal bleeding within 6 months before consent
History of bleeding diathesis or coagulopathy or refuses blood transfusions
Polycystic kidney disease, unilateral kidney, or history of renal transplant
Scheduled or planned surgery that may affect study endpoints, in opinion of Investigator
Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement (e.g., upper arm circumfer-
ence outside cuff size ranges available by geography or arrhythmia that interferes with automatic monitor’s pulse sensing)
Severe cardiac valve stenosis for which a significant reduction of blood pressure is contraindicated, in opinion of investigator
Documented confounding medical condition that may adversely affect the safety of the subject, in opinion of investigator (e.g., clinically signifi-
cant peripheral vascular disease or aortic aneurysm)
Currently prescribed narcotic drugs or methadone
Currently taking anti-mineralocorticoid medications, unless weaned off by ≥ 8 weeks prior to Screening Visit 1
Known unresolved history of drug use or alcohol dependency, lacks ability to comprehend or follow instructions, or would be unlikely or unable 
to comply with study follow-up requirements
Currently enrolled in a concurrent investigational drug or device study, unless approved by study sponsor
Pregnant, nursing or planning to become pregnant during course of the study or follow-up
Works night shifts
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The investigator performing catheterization and desig-
nated study staff are blinded to a subject’s randomization 
up until renal angiography is completed and eligibility 
is confirmed. Subjects are blinded during renal angiog-
raphy by a combination of conscious sedation, sensory 
isolation (e.g., blindfold and music), and lack of familiar-
ity with the procedural details and duration. Each study 
site has designated staff that are blinded to subject treat-
ment group and responsible for obtaining office blood 
pressure and ambulatory blood pressure measurements. 
Blinding effectiveness of the subject will be assessed at 
discharge and follow-up visits through the 6-month blind-
ing period by asking blinded staff and the study subject 
which group they believe the subject was randomized to. 
The unblinded personnel will not see the subject until the 
scheduled unblinding visit was completed.
Symplicity Spyral catheter
The Symplicity Spyral multi-electrode renal denervation 
system is composed of the single-use disposable Symplic-
ity Spyral catheter and the reusable Symplicity G3™ radi-
ofrequency generator. Together, these components deliver 
low-level radiofrequency energy through the wall of the 
renal artery to denervate the renal nerves. The Symplicity 
Spyral catheter and Symplicity G3 generator received CE 
Mark in October 2013 and have been commercially avail-
able in selected geographies outside the United States, 
Canada, and Japan. Details of the Symplicity catheter 
design have been previously described [15].
Procedure
For subjects randomized to the denervation group, the 
renal artery denervation procedure is performed accord-
ing to the Symplicity Spyral catheter Instructions for Use, 
Symplicity G3 generator User Manual, and associated 
training provided by the sponsor. Therefore, based on 
sponsor recommendations, ablations are to be performed 
in all accessible renal arterial branch vessels with diam-
eters between 3 and 8 mm, including accessory, branch, 
and main renal arteries that are outside of the renal paren-
chyma. Initial placement of the Symplicity Spyral catheter 
should be just proximal to the renal parenchyma, using 
fluoroscopic imaging for guidance. The investigators are 
instructed to perform as many ablations within a segment 
as anatomy permits, starting distally and working proxi-
mally without overlapping treatment zones. If the vessel 
segment cannot accommodate all four electrodes, then it is 
recommended to position a smaller number of electrodes 
and deselect the electrodes that are outside of the target 
segment. Ablations should be avoided in bifurcations and 
within 5 mm of areas with calcification, atheroma, or 
stented lesions.
For subjects in either group, preprocedural treatment with 
anxiolytic and/or analgesic medications may be considered 
and is at the discretion of the investigator. Additional doses 
of anxiolytic and/or analgesic medications are permitted 
during the procedure to be timed with ablations as appro-
priate. Upon completion of the procedure, hemostasis at the 
puncture site should be achieved by manual compression or 
use of closure devices.
Table 1  (continued)
ABPM ambulatory blood pressure monitoring, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, MDRD modification of 
diet in renal disease, SBP systolic blood pressure
a For SPYRAL HTN-ON MED Expansion, criterion applies when subject is on 1–3 antihypertensive medications at ≥ 50% of the maximum 
manufacturer’s dosage. Antihypertensive medication classes must include a thiazide-type diuretic, a dihydropyridine calcium channel blocker, 
an angiotensin-converting enzyme-I/angiotensin-II receptor blocker, or a beta-blocker. Subject must be on a stable dose of each medication for at 
least 6 weeks before Screening Visit 1 and up to Screening Visit 2. When prescribed other qualifying medications, 12.5 mg hydrochlorothiazide 
is acceptable as the minimum dosage. In Japan, subjects may be prescribed less than 50% of the maximum manufacturer’s recommended dosage 
of a thiazide-type diuretic, per standard of care
b Applied at Screening Visits 1 and 2 for both trials
c Applied at Screening Visit 2 for HTN-OFF MED, Screening Visits 1 and 2 for SPYRAL HTN-ON MED Expansion
d Applied at Screening Visit 2 for both trials
e ABPM is considered valid if the number of successful daytime readings captured is ≥ 21 and the number of successful nighttime readings cap-
tured is ≥ 12
f For SPYRAL HTN-ON MED Expansion, ABPM device is applied after witnessed ingestion of antihypertensive medications
g eGFR calculation specific to Japanese subjects will be used for subjects enrolled in Japan
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Fig. 1  Subject flow through the SPYRAL HTN-OFF MED Pivotal (a) and SPYRAL HTN-ON MED Expansion (b) trials; ABPM ambulatory 
blood pressure monitor, DBP diastolic blood pressure, SBP systolic blood pressure
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Endpoints
The primary efficacy endpoint is baseline-adjusted change in 
24 h ambulatory SBP from baseline to 3 months (SPYRAL 
HTN-OFF MED Pivotal) or 6 months (SPYRAL HTN-ON 
MED Expansion) post-procedure. SPYRAL HTN-OFF 
MED Pivotal includes a powered secondary efficacy end-
point, which is baseline-adjusted change in office SBP from 
baseline to 3 months. All endpoints, including secondary 
safety, efficacy, and quality of life measures, are summarized 
in Table 2. The primary safety endpoint for both trials is the 
1-month incidence of major adverse events and occurrence 
Fig. 1  (continued)
296 Clinical Research in Cardiology (2020) 109:289–302
1 3
Table 2  Primary and secondary endpoints of the SPYRAL HTN-OFF MED Pivotal and SPYRAL HTN-ON MED Expansion trials
ABPM ambulatory blood pressure monitoring, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, NA not applicable, SBP 
systolic blood pressure, SF-36 Short Form (36) Health Survey, TIMI thrombolysis in myocardial infarction
a Defined as composite of all-cause mortality, end-stage renal disease, significant embolic event resulting in end-organ damage, renal artery per-
foration or dissection requiring intervention, vascular complications, hospitalization for hypertensive crisis not related to confirmed non-adher-
ence with medications or the protocol, and new renal artery stenosis > 70% (confirmed by angiography and as determined by the angiography 
core laboratory)
b 1 month post-randomization or 6 months for new renal artery stenosis
c Change from baseline values acquired at Screening Visit 2
d SPYRAL HTN-ON MED Expansion trial does not include a powered secondary efficacy endpoint
e Procedural secondary safety endpoints compared between groups only at 1 month after index procedure in SPYRAL HTN-OFF MED Pivotal
f Chronic secondary safety endpoint compared between groups only at 3, 6, 12, 24, and 36 months after index procedure in SPYRAL HTN-OFF 
MED Pivotal and SPYRAL HTN-ON MED Expansion
g TIMI definition of major bleeding included intracranial hemorrhage, ≥ 5 g/dL decrease in hemoglobin concentration, ≥ 15% absolute decrease in 
hematocrit, or death due to bleeding within 7 days of procedure
h Confirmed by angiography and as determined by angiography core laboratory
i Composite safety secondary endpoint includes same events as those in the powered primary safety endpoint but assessed at 3, 6, 12, 24, and 
36 months
j Compared between groups at 3, 6, 12, 24, and 36 months after index procedure
k SPYRAL HTN-OFF MED Pivotal only
Endpoint Time after index procedure
SPYRAL HTN-OFF MED Pivotal SPYRAL HTN-ON MED Expansion
Powered primary safety endpoint 1 monthb 1 monthb
Incidence of major adverse  eventsa
Powered primary efficacy endpoint 3 months 6 months
Baseline-adjusted change from baseline in SBP, measured by 24 h  ABPMc
Powered secondary efficacy endpoint 3 months NAd
Baseline-adjusted change from baseline in office SBP
Secondary safety endpoints 1, 3, 6, 12, 24, and 36 months 1, 3, 6, 12, 24, and 36 months
Significant embolic event resulting in end-organ  damagee
Renal artery perforation requiring  interventione
Renal artery dissection requiring  interventione
Vascular  complicationse
All-cause  mortalityf
End-stage renal disease
≥ 40% decline in eGFR
New myocardial infarction
New stroke
Renal artery reintervention
Major bleeding according to TIMI  definitiong
Increase in serum creatinine > 50% from Screening Visit 2
New renal artery stenosis > 70%h
Hospitalization for hypertensive crisis not related to confirmed non-adherence 
or the protocol
Composite safety secondary endpointi 3, 6, 12, 24, and 36 months 3, 6, 12, 24, and 36 months
Secondary efficacy endpoints 1, 3, 6, 12, 24, and 36 months 1, 3, 6, 12, 24, and 36 months
Change from baseline in SBP, by 24 h  ABPMc,j
Change from baseline in office  SBPc
Change from baseline in DBP, by 24 h  ABPMc,j
Change from baseline office in  DBPc
Incidence of achieving target office SBP (< 140 mm Hg)
Quality-of-life measures
EuroQol-5D
SF-36k
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of renal artery stenosis at 6 months following randomization. 
Major adverse events are defined as a composite of all-cause 
mortality, end-stage renal disease, significant embolic event 
resulting in end-organ damage, renal artery perforation or 
dissection requiring intervention, vascular complications, 
hospitalization for hypertensive crisis (not related to con-
firmed nonadherence with medications or the protocol), and 
new renal artery stenosis > 70% (confirmed by angiography 
and as determined by the angiography core laboratory). 
Details on blood pressure measurement methodology are 
provided in the Supplement.
Safety and quality control
A Data Safety Monitoring Board (DSMB) has been estab-
lished to monitor the health, safety, and welfare of subjects. 
The DSMB is composed of physicians with experience in 
clinical studies of hypertension and/or cardiovascular medi-
cine and one biostatistician with experience in the analysis 
of clinical studies. The DSMB members are not investigators 
in the study and are independent of the sponsor. Prior to the 
first DSMB review, guidelines were established for the iden-
tification and evaluation of significant safety findings and/or 
increased frequency of events that might impact the rights, 
safety, or welfare of subjects. All materials, discussions, and 
proceedings of the DSMB are completely confidential. The 
proceedings of each DSMB are recorded in minutes. The 
DSMB Chairperson is responsible for providing a written 
recommendation regarding study conduct (e.g., continue as 
planned, specify a modification, or termination).
An independent Clinical Events Committee (CEC) has 
also been established to adjudicate any safety endpoints. 
The CEC is composed of physicians who have experience 
in clinical studies in hypertension and/or cardiovascular 
indications. The CEC members are not investigators in the 
study and are independent of the sponsor. Guidelines for 
the adverse event adjudication process were established at 
the first CEC meeting. Details on the definitions used for 
adjudication, the adjudication process, and the reporting of 
outcomes are provided in the CEC Charter. The proceedings 
of each CEC meeting are recorded in minutes.
All programming and endpoint analyses will be indepen-
dently performed by Cytel Inc. (Cambridge, MA, USA).
Statistics
Bayesian design and prespecified interim analyses
A Bayesian trial design was proposed that allows for pre-
specified interim analyses to take place in addition to lever-
aging pilot study data. For SPYRAL HTN-OFF MED Piv-
otal, assuming 15% attrition, interim analyses are expected 
to occur first term at approximately 210 and second-term 
when approximately 240 subjects have evaluable data, with 
a maximum sample size of 300 evaluable subjects if the 
trial does not stop at either the first or second interim look. 
The time from randomization of the first cohort to the sec-
ond cohort and final cohort, if applicable, is lengthy due to 
stringent eligibility criteria and subsequent slow randomi-
zation rates. For SPYRAL HTN-ON MED Expansion, the 
expected sample sizes are 149 and 187 evaluable subjects, 
with a maximum sample size of 221 evaluable subjects. 
Actual numbers of evaluable subjects will be determined 
by the actual attrition, which is currently expected to be 
15%. At each prespecified interim analysis, enrollment may 
be stopped for efficacy or expected futility. For SPYRAL 
HTN-OFF MED Pivotal, the primary and secondary efficacy 
endpoints will be evaluated during these prespecified interim 
looks, and enrollment will only stop at an interim analysis 
if both endpoints meet the following stopping criteria. For 
SPYRAL HTN-ON MED Expansion, the primary efficacy 
endpoint will be evaluated at prespecified interim looks. A 
distinction between the stopping for efficacy and futility is 
that the former is based solely on the observed/evaluable 
data, whereas the latter involves the observed/evaluable data, 
as well as imputation for subjects without evaluable data or 
not yet randomized.
The underlying model is a Bayesian analogue of the anal-
ysis of covariance (ANCOVA) model for SBP change from 
baseline, yi , adjusted for baseline blood pressure and treat-
ment arm. Due to a Bayesian power prior approach being 
used, a non-standard parameterization for the ANCOVA 
model is used to allow for informative prior distributions 
to be placed separately on the RDN and control arm effects:
where yi denotes the change from baseline in BP at follow-
up, subscripts i denote the i th subject with evaluable data, 
I(i ∈ t) = 1 if subject i is randomized to renal denervation, or 
= 0 if randomized to sham control, and 훽 is the regression coef-
ficient for the adjustment in mean-centered baseline BP, xi . 
Similarly, I(i ∈ c) = 1 if subject i is randomized to sham 
control, and 0 otherwise. Letting 휇 = 휇t − 휇c denote the 
baseline-adjusted treatment effect of SBP change compar-
ing renal denervation to sham control, at either prespecified 
interim (or final) look, the posterior probability of 휇 being 
less than zero is calculated. If this probability is > 0.975 , 
the trial is stopped, and efficacy declared. Type I error rates 
were calculated by extensive simulation under this interim 
analysis scheme (details below).
At each prespecified interim look, a test for futility is 
also made. In this case, the probability of futility is based 
on the maximum study size of evaluable subjects, which 
requires us to impute the outcomes for subjects who have not 
yet been enrolled. If the posterior probability of 𝜇 < 0 from 
yi = 휇tI(i ∈ t) + 휇cI(i ∈ c) + xi훽 + 휀i;휀i ∼ N
(
0, 휎2
)
,
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this calculation is < 0.05 for the primary efficacy endpoint 
(and secondary efficacy endpoint in the context of SPYRAL 
HTN-OFF MED Pivotal), then the study will have met the 
futility boundary and enrollment will be stopped. If the study 
stops for efficacy at either the first or second prespecified 
interim analysis, then any additional subjects that have been 
enrolled before the decision to stop has been made will not 
be part of the primary endpoint analysis, but will be com-
bined with the interim analysis cohort and analyzed as a 
secondary efficacy analysis.
Since the pilot study data for SPYRAL HTN-OFF MED 
Pivotal and SPYRAL HTN-ON MED Expansion trials were 
collected under similar enrollment criteria and are pub-
lished, these data are leveraged using a novel extension of 
the Bayesian power prior method, which was proposed by 
a Medical Device Innovative Consortium (MDIC) working 
group [5, 6, 16]. In brief, the first step involves updating flat 
prior distributions for 휇t and 휇c using the pilot study data 
only. These updated distributions are used as a prior distri-
bution for analyzing the pivotal data. To allow for potential 
dissimilarities between the pilot studies and pivotal/pro-
spective data, the aforementioned prior distributions will 
be down-weighted via separate power parameters, 훼t and 훼c , 
respectively [9]. The power parameter can range between 0 
(equivalent to ignoring all the pilot study data) and 1 (equiv-
alent to complete pooling of the pilot study data). In addi-
tion, a diffuse normal prior distribution for 훽 and a flat prior 
on log(휎) are used to estimate the posterior distribution. A 
diagram illustrating the Bayesian discount prior methodol-
ogy is provided in Fig. 2.
In practice, power parameters can be specified in 
advance or treated as random and estimated in the model. 
For this trial, we use a ‘dynamic borrowing’ approach 
based on the similarity of pilot study data to that of the 
pivotal/prospective data [17]. Namely, to determine the 
power parameters, a statistical comparison is first made 
between the pilot studies and pivotal/prospective data in 
each treatment arm following the approach described by 
Haddad and colleagues yielding comparison statistics pt 
and pc , for the renal denervation and sham control arms, 
respectively [8]. A ‘p value’ close to 0 indicates a high 
probability that the pivotal/prospective data and pilot 
study data come from different populations, meaning that 
discounting should be applied to reduce the influence of 
the prior. Conversely, a p value close to 1 indicates that 
there is a high probability that the pivotal/prospective 
data and pilot study data come from similar populations 
and minimal discounting should be applied. The p values 
are transformed (also referred to as discounting) using a 
prespecified Weibull function with shape parameter k = 3 
and scale parameters 휆 = 0.25 (SPYRAL HTN-ON MED 
Expansion) and 0.50 (SPYRAL HTN-OFF MED Pivotal); 
these functions were selected through tuning of the operat-
ing characteristics via extensive simulations.
Fig. 2  Diagrammatic illustra-
tion of the Bayesian discount 
prior methodology. Top panel: 
the prior data have similar 
outcomes to the current/pivotal 
data, meaning that nearly all 
information is utilized in the 
primary analysis. Middle panel: 
there is some overlap, meaning 
that the partial information is 
carried over into the primary 
analysis. Bottom panel: the 
outcomes are disparate, mean-
ing that little-to-none data of 
the information from the prior 
are utilized for the primary 
analysis. Figure represents three 
hypothetical scenarios only
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Determination of sample size and prespecified 
interim looks
For both the SPYRAL HTN-OFF MED Pivotal and 
SPYRAL HTN-ON MED Expansion cohorts, pilot study 
data are already available for 80 subjects. These data will 
be incorporated into the study via the aforementioned 
power prior methodology. As described earlier, sample 
sizes for SPYRAL HTN-OFF MED Pivotal and SPYRAL 
HTN-ON MED Expansion will vary due to the adap-
tive nature of the trial, and precise numbers of evaluable 
subjects will depend on the observed attrition rate. For 
SPYRAL HTN-OFF MED Pivotal and the first 26 rand-
omized subjects in SPYRAL HTN-ON MED Expansion, 
subjects were randomized 1:1 to renal denervation or sham 
control. For subject 27 onwards in the SPYRAL HTN-ON 
MED Expansion study, randomization will be 2:1 for renal 
denervation to sham control following a protocol revision 
during the trial.
Each study includes prespecified interim analyses, 
at which point enrolment may be stopped for futility or 
expected success, as described previously. For SPYRAL 
HTN-OFF MED Pivotal, these will occur after the 210th 
and 240th subjects have reached their 3-month endpoint 
and have evaluable data, and for SPYRAL HTN-ON MED 
Expansion after the 175th and 220th subjects (excluding 
the 80 pilot study subjects) have reached their 6-month 
endpoint and have evaluable data. Enrolment will continue 
to the maximum study size of evaluable subjects if the 
study does not stop at either prespecified interim look.
In each study, the operating characteristics (including 
type I error and power) were determined using extensive 
simulations. A total of 8000 trial simulations were per-
formed to estimate the power and 15,000 simulations to esti-
mate the type I error. Interim look (and maximum) sample 
sizes as well as discount function parameters were tuned 
during simulation to achieve acceptable trial characteristics. 
Final study design parameter assumptions are described in 
Table 3. For SPYRAL HTN-OFF MED Pivotal, the over-
all trial power to detect a treatment difference of − 4.0 mm 
Hg in mean 24 h SBP was 94% with one-sided type I error 
2.9% for the primary endpoint. Power at prespecified interim 
looks varied between 83 and 89%. For SPYRAL HTN-ON 
MED Expansion, the overall trial power to detect a treatment 
difference of − 5.0 mm Hg was 96% with type I error 3.0%. 
Power at first and second prespecified interim looks was 89% 
and 94%, respectively.
Analysis populations
The intention-to-treat population includes all randomized 
subjects analyzed according to their randomized treatment 
group. Safety outcomes, and office and ambulatory blood 
pressure outcomes will be assessed at each follow-up visit 
in this population. Subjects who met antihypertensive med-
ication escape criteria will have blood pressure measure-
ments analyzed with LOCF. To apply LOCF, valid office 
and ambulatory blood pressure measurements taken prior 
to the subject’s escape date will be used out to 3 months 
(SPYRAL HTN-OFF MED Pivotal) or 6 months (SPYRAL 
Table 3  Parameter assumptions for the SPYRAL HTN-OFF MED Pivotal and SPYRAL HTN-ON MED Expansion trials and summary of the 
available pilot study data used in the analysis
SD standard deviation, SE standard error
Simulation parameter SPYRAL HTN-OFF MED Pivotal SPYRAL HTN-ON MED Expansion
Primary efficacy endpoint Secondary efficacy endpoint Primary efficacy endpoint
Pilot studies
 Pilot study treatment arm baseline-adjusted 
mean/SE
− 5.30/1.65 mm Hg − 9.69/2.20 mm Hg − 8.8/1.8 mm Hg
 Pilot study treatment arm N 35 37 36
 Pilot study control arm baseline-adjusted 
mean/SE
− 0.74/1.62 mm Hg − 2.54/2.09 mm Hg − 1.8/1.8 mm Hg
 Pilot study control arm N 36 41 36
 Maximum pilot study subjects 35 + 36 = 71 37 + 41 = 78 36 + 36 = 72
Pivotal study
 Pivotal/prospective study expected treatment 
difference
4.0 mm Hg 6.5 mm Hg 5.0 mm Hg
 Pivotal/prospective study treatment arm 
mean/SD
− 4.74/12 mm Hg − 9.04/16 mm Hg − 6.8/12 mm Hg
 Pivotal/prospective study control arm mean/
SD
− 0.74/12 mm Hg −2.54/16 mm Hg − 1.8/12 mm Hg
 Weibull discount function parameters Shape: k = 3, scale: 
λ = 0.5
Shape: k = 3, scale: λ  = 0.5 Shape: k = 3, scale: λ  = 0.25
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HTN-ON MED Expansion) in this population. The modi-
fied intention-to-treat population does not include subjects 
who met antihypertensive medication escape criteria. Office 
and ambulatory blood pressure outcomes will be assessed 
through 3 months (SPYRAL HTN-OFF MED Pivotal) or 
6 months (SPYRAL HTN-ON MED Expansion) in this 
population. The per protocol population includes the modi-
fied intention-to-treat population, but excludes subjects 
who do not maintain medication adherence as assessed via 
blood and/or urine testing, and/or have renal anatomy that 
is ineligible for treatment as assessed by renal angiography 
and excludes subjects who did not receive their randomized 
treatment. Office and ambulatory blood pressure outcomes 
will be assessed through 3 months (SPYRAL HTN-OFF 
MED Pivotal) or 6  months (SPYRAL HTN-ON MED 
Expansion) in this population.
Subgroup analyses
Subgroup analyses are planned to assess consistency of 
results between subgroups based on the following demo-
graphic or clinical characteristics: gender, age at base-
line < 65 vs. ≥ 65 years, BMI by tertiles (kg/m2), presence or 
absence of type 2 diabetes, current smokers vs. non-smokers, 
baseline eGFR < 60 vs. ≥ 60 mL/min/1.73 m2, presence or 
absence of obstructive sleep apnea, US vs. OUS subjects, 
US African-American vs. US non-African-American sub-
jects, European vs. Japanese vs. Australian subjects, base-
line ambulatory SBP by tertiles and medians (mmHg), base-
line office SBP by tertiles and medians (mmHg), baseline 
ambulatory heart rate by tertiles and medians (bpm), base-
line office heart rate by tertiles and medians (bpm), 24 h 
Pulse Pressure < 60 vs. ≥ 60 mm Hg, presence or absence of 
orthostatic hypertension at baseline, presence or absence of 
orthostatic tachycardia at baseline, plasma renin activity at 
baseline < 0.65 vs. ≥ 0.65 ng/mL/h, aldosterone/renin ratio 
at baseline by tertiles (ng/dL), aldosterone at baseline by 
tertiles (ng/dL), tertile analysis by total number of ablations 
performed, tertile analysis by total number of ablations per-
formed in branch vessels, tertile analysis by total number 
of ablations performed in main renal artery vessels, tertile 
analysis by total number of 45 s ablations performed, and 
medication adherent vs. non-adherent subjects.
Summaries and comparisons
Continuous outcomes will be summarized with means, 
standard deviations, medians, and minimums and maxi-
mums. Categorical outcomes will be summarized as counts 
and percentages. Statistical comparisons between treatment 
groups will be made using t tests for continuous outcomes 
and Chi-square or Fisher’s exact test (depending on overall 
event rates) for categorical outcomes. Paired t tests will be 
used to compare changes from baseline to follow-up. Addi-
tionally, conventional ANCOVA treatment effect estimates 
will be determined for pivotal/prospective data only and 
the pooled pivotal/prospective data. A secondary analysis 
will be performed for both efficacy endpoints where miss-
ing outcome data are imputed using a multiple imputation 
procedure. Missing office and ambulatory primary endpoint 
outcomes will be imputed using baseline SBP, treatment 
group, age, gender, and BMI. Unless otherwise specified, 
a two-sided 0.05 level of significance will be used to deter-
mine a significant difference between treatment groups. All 
non-Bayesian statistical analyses will be performed using 
SAS for Windows (version 9.2 or higher; SAS Institute, 
Cary, NC, USA). The Bayesian analysis will be performed 
using R (version 3.6.0 or higher; The R Foundation, Vienna, 
Austria) using the bayesDP package [18].
Analysis of primary safety endpoint
A performance goal approach will be used to analyze the pri-
mary safety endpoint. The safety performance goal for major 
adverse event rate was based on comparison to event rates 
of other renal interventions [19–27]. The events reported 
were different among studies; however, for a subset of stud-
ies, rates were estimated for a composite of events that was 
similar to the definition of composite major adverse events 
in this study. The major adverse event rate from these studies 
was 7.1%, which will be used as the performance goal for the 
primary safety endpoint. The primary safety null and alter-
native hypotheses are H0: π ≥ 7.1% vs. Ha: π < 7.1%, where 
π is the major adverse event rate for subjects undergoing 
renal denervation. Under the assumption that the true rate 
is 3.5%, and using a one-sided 0.05 level of significance, 
an evaluable sample size of 253 renal denervation subjects 
yields 80% power to reject the null hypothesis in favour of 
the alternative based on a binomial exact test. To account 
for 5% of subjects lost to follow-up, a total of 266 rand-
omized subjects will be required. Data from the pilot studies, 
the SPYRAL HTN-OFF MED Pivotal study, the SPYRAL 
HTN-ON MED Expansion study, and crossovers will com-
prise the sample cohort.
Summary
In conclusion, the SPYRAL HTN-OFF MED Pivotal and 
SPYRAL HTN-ON MED Expansion trials allow a unique 
opportunity to explore the effect of renal denervation on blood 
pressure both in the absence of, and presence of, antihyperten-
sive medications, respectively. The trials leverage randomized 
comparisons to blinded sham controls which allow for an 
informative, nonbiased approach. The SPYRAL HTN-OFF 
MED Pivotal and SPYRAL HTN-ON MED Expansion trials 
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have a unique Bayesian design that will exploit historical data 
from the pilot studies and use a discount function to adjust 
the influence of the historical data based on level of agree-
ment with data from the prospectively powered studies. There 
are multiple strengths to using a Bayesian approach in this 
type of study. First, the ability to leverage information from a 
prior trial of similar design increases the power of the current 
trial, and conversely, decreases the overall number of subjects 
required for randomization in the current trial. Second, the 
adaptive nature of a Bayesian design supports interim looks 
with stopping for efficacy or futility. Finally, a novel Bayesian 
approach makes efficient use of prior information and further 
advances a development program by seamlessly combining 
trials of a similar clinical design.
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